1 / 6

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis

NidhiNehani
Download Presentation

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead

  2. Nuclear factor-kappa B (NF-kB) NF-kB inhibitors therapeutics pipeline in 2017 The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation. Access Report Summary with Detailed TOC on "Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis

  3. Nuclear factor-kappa B (NF-kB) Insights on procedure segments According to the research findings, most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source. Increasing prevalence of cancer drives the growth of NF-kB inhibitors drug development According to the National Cancer Institute, the prevalence of cancer has been increasing at a very high rate. Therefore, companies are focusing on developing target specific and personalized medicine for the better treatment with reduced adverse events. Thus, NF-kB inhibitors therapeutics pipeline is likely to grow significantly, in the future, for the treatment of various diseases including cancer and chronic inflammation.

  4. Nuclear factor-kappa B (NF-kB) Various collaborations for NF-kB inhibitors drug development In May 2014, AnGes MG, Inc. and Shionogi & Co., Ltd. entered in a license agreement to co-develop NF-kB decoy oligodeoxynucleotide for the treatment of atopic dermatitis. Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others.

  5. Nuclear factor-kappa B (NF-kB) Download report sample at: https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related